Many innovative pharmaceutical companies looking to diversify consider entering the small-molecule generics business, which they view as a logical adjacent space with comparatively low barriers to entry, and one that is synergetic with their existing business.
An IMS data-driven study of 4,500 generics launches confirms the importance of a strong local presence, large global scale, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?